Cochrane COVID-19 Studienregister
Studienbericht
NCT05043324Erstmals veröffentlicht: 2021 Sept 14Letzte Aktualisierung: 2021 Sept 14

Prevention and Treatment of Patient Before, During, and After Covid-19 Infection

  1. Studientyp
  2. Interventional
  1. Studienziel
  2. Treatment and Management
  1. Studiendesign
  2. Parallel/Crossover
  1. Interventionszuordnung
  2. Non-randomised
Referenzdatensätze

Prevention and Treatment of Patient Before, During, and After Covid-19 Infection

NCT05043324
Eintrag in Studienregister
Keine Ergebnisse
AntiCov-220 prevents and treats before, during, and after infection with SARS-Cov-2. The composition is fractionally extracted from herbs, using flavonoids, isoflavonoids, and pregnenolone in combination with ascorbic acid as the key compounds in preventing and killing SARS-CoV-2; increase antibodies and protect cells; supplementing precursors to help the body strengthen antibodies and reduce the risk of infection; destroy spike protein, toxic protein, help prevent blood clots causing stroke; restore the physiological function of cells after virus infection; helps the body to stabilize the amount of cortisol in the blood as well as stabilize the production of specific antibodies. The composition participates in anti-inflammatory and cells protecting process, bringing blood cortisol, B-lymphocytes, Cyfra 21-1, WBC, CRP, fever, dyspnea, and other signs of respiratory tract inflammation to a normal state and normal limit